{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:07:54Z","timestamp":1793822874778,"version":"4.6.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The major challenge to controlling the COVID pandemic is the rapid mutation rate of the SARS-CoV-2 virus, leading to the escape of the protection of vaccines and most of the neutralizing antibodies to date. Thus, it is essential to develop neutralizing antibodies with broad-spectrum activity targeting multiple SARS-CoV-2 variants. Here, we report a synthetic nanobody (named C5G2) obtained by phage display and subsequent antibody engineering. C5G2 has a single-digit nanomolar binding affinity to the RBD domain and inhibits its binding to ACE2 with an IC<jats:sub>50<\/jats:sub> of 3.7\u00a0nM. Pseudovirus assays indicated that monovalent C5G2 could protect the cells from infection with SARS-CoV-2 wild-type virus and most of the viruses of concern, i.e., Alpha, Beta, Gamma and Omicron variants. Strikingly, C5G2 has the highest potency against Omicron BA.1 among all the variants, with an IC<jats:sub>50<\/jats:sub> of 4.9\u00a0ng\/mL. The cryo-EM structure of C5G2 in complex with the spike trimer showed that C5G2 binds to RBD mainly through its CDR3 at a conserved region that does not overlap with the ACE2 binding surface. Additionally, C5G2 binds simultaneously to the neighboring NTD domain of the spike trimer through the same CDR3 loop, which may further increase its potency against viral infection. Third, the steric hindrance caused by FR2 of C5G2 could inhibit the binding of ACE2 to RBD as well. Thus, this triple-function nanobody may serve as an effective drug for prophylaxis and therapy against Omicron as well as future variants.<\/jats:p>","DOI":"10.1186\/s12951-022-01619-y","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T19:03:32Z","timestamp":1663268612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode"],"prefix":"10.1186","volume":"20","author":[{"given":"Dongping","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linli","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongming","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"issue":"10223","key":"1619_CR1","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","volume":"395","author":"JF Chan","year":"2020","unstructured":"Chan JF, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514\u201323.","journal-title":"Lancet"},{"issue":"10223","key":"1619_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet. 2020;395(10223):497\u2013506.","journal-title":"Lancet"},{"issue":"7798","key":"1619_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270\u20133.","journal-title":"Nature"},{"issue":"2","key":"1619_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls AC, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281\u201392.","journal-title":"Cell"},{"issue":"9","key":"1619_CR5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","volume":"41","author":"Y Huang","year":"2020","unstructured":"Huang Y, et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141\u20139.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"1619_CR6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","volume":"78","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Pohlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 Is essential for infection of human lung cells. Mol Cell. 2020;78(4):779\u201384.","journal-title":"Mol Cell"},{"issue":"1","key":"1619_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/v13010109","volume":"13","author":"X Xia","year":"2021","unstructured":"Xia X. Domains and functions of spike protein in sars-Cov-2 in the context of vaccine design. Viruses. 2021;13(1):109\u201325.","journal-title":"Viruses"},{"issue":"7","key":"1619_CR8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","volume":"17","author":"S Xia","year":"2020","unstructured":"Xia S, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020;17(7):765\u20137.","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"1619_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271\u201380.","journal-title":"Cell"},{"issue":"6523","key":"1619_CR10","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1126\/science.abe3255","volume":"370","author":"M Schoof","year":"2020","unstructured":"Schoof M, et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. 2020;370(6523):1473\u20139.","journal-title":"Science"},{"key":"1619_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe6230","author":"PA Koenig","year":"2021","unstructured":"Koenig PA, et al. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science. 2021. https:\/\/doi.org\/10.1126\/science.abe6230.","journal-title":"Science"},{"key":"1619_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2021.106003","volume":"190","author":"WH Chen","year":"2022","unstructured":"Chen WH, et al. Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate. Protein Expr Purif. 2022;190: 106003.","journal-title":"Protein Expr Purif"},{"issue":"7866","key":"1619_CR13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41586-021-03676-z","volume":"595","author":"J Xu","year":"2021","unstructured":"Xu J, et al. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature. 2021;595(7866):278\u201382.","journal-title":"Nature"},{"issue":"6504","key":"1619_CR14","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1126\/science.abc6952","volume":"369","author":"X Chi","year":"2020","unstructured":"Chi X, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650\u20135.","journal-title":"Science"},{"issue":"7821","key":"1619_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","volume":"584","author":"L Liu","year":"2020","unstructured":"Liu L, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584(7821):450\u20136.","journal-title":"Nature"},{"issue":"11","key":"1619_CR16","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.3390\/v13112214","volume":"13","author":"Q Tang","year":"2021","unstructured":"Tang Q, Owens RJ, Naismith JH. Structural biology of nanobodies against the Spike protein of SARS-CoV-2. Viruses. 2021;13(11):2214\u201328.","journal-title":"Viruses"},{"issue":"9","key":"1619_CR17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41594-020-0469-6","volume":"27","author":"J Huo","year":"2020","unstructured":"Huo J, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2020;27(9):846\u201354.","journal-title":"Nat Struct Mol Biol"},{"issue":"7819","key":"1619_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi R, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584(7819):120\u20134.","journal-title":"Nature"},{"issue":"3","key":"1619_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.chom.2020.06.010","volume":"28","author":"J Huo","year":"2020","unstructured":"Huo J, et al. Neutralization of SARS-CoV-2 by destruction of the prefusion Spike. Cell Host Microbe. 2020;28(3):445\u201354.","journal-title":"Cell Host Microbe"},{"issue":"7815","key":"1619_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto D, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290\u20135.","journal-title":"Nature"},{"issue":"1","key":"1619_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","volume":"182","author":"Y Cao","year":"2020","unstructured":"Cao Y, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells. Cell. 2020;182(1):73\u201384.","journal-title":"Cell"},{"issue":"7819","key":"1619_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju B, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584(7819):115\u20139.","journal-title":"Nature"},{"key":"1619_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.sbi.2013.11.003","volume":"24","author":"JJ Adams","year":"2014","unstructured":"Adams JJ, Sidhu SS. Synthetic antibody technologies. Curr Opin Struct Biol. 2014;24:1\u20139.","journal-title":"Curr Opin Struct Biol"},{"issue":"9","key":"1619_CR24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.5483\/BMBRep.2015.48.9.120","volume":"48","author":"H Shim","year":"2015","unstructured":"Shim H. Synthetic approach to the generation of antibody diversity. BMB Rep. 2015;48(9):489\u201394.","journal-title":"BMB Rep"},{"issue":"2","key":"1619_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10059-009-0028-9","volume":"27","author":"HY Yang","year":"2009","unstructured":"Yang HY, et al. Construction of a large synthetic human scFv library with six diversified CDRs and high functional diversity. Mol Cells. 2009;27(2):225\u201335.","journal-title":"Mol Cells"},{"issue":"1","key":"1619_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/1744666X.2020.1857733","volume":"17","author":"WH Boehncke","year":"2021","unstructured":"Boehncke WH, Brembilla NC, Nissen MJ. Guselkumab: the first selective IL-23 inhibitor for active psoriatic arthritis in adults. Expert Rev Clin Immunol. 2021;17(1):5\u201313.","journal-title":"Expert Rev Clin Immunol"},{"issue":"10230","key":"1619_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115\u201325.","journal-title":"Lancet"},{"issue":"1","key":"1619_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1006\/jmbi.1999.3444","volume":"296","author":"A Knappik","year":"2000","unstructured":"Knappik A, et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol. 2000;296(1):57\u201386.","journal-title":"J Mol Biol"},{"key":"1619_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775\u201397.","journal-title":"Annu Rev Biochem"},{"key":"1619_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00977","author":"G Gonzalez-Sapienza","year":"2017","unstructured":"Gonzalez-Sapienza G, Rossotti MA, Tabares-da Rosa S. Single-domain antibodies as versatile affinity reagents for analytical and diagnostic applications. Front Immunol. 2017. https:\/\/doi.org\/10.3389\/fimmu.2017.00977.","journal-title":"Front Immunol"},{"issue":"4","key":"1619_CR31","first-page":"277","volume":"74","author":"S Muyldermans","year":"2001","unstructured":"Muyldermans S. Single domain camel antibodies: current status. J Biotechnol. 2001;74(4):277\u2013302.","journal-title":"J Biotechnol"},{"issue":"1","key":"1619_CR32","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1038\/s41467-021-25480-z","volume":"12","author":"J Huo","year":"2021","unstructured":"Huo J, et al. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. Nat Commun. 2021;12(1):5469.","journal-title":"Nat Commun"},{"issue":"6","key":"1619_CR33","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.chom.2020.04.023","volume":"27","author":"Y Wu","year":"2020","unstructured":"Wu Y, et al. Identification of human single-domain antibodies against SARS-CoV-2. Cell Host Microbe. 2020;27(6):891\u20138.","journal-title":"Cell Host Microbe"},{"issue":"12","key":"1619_CR34","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1073\/pnas.0505379103","volume":"103","author":"E De Genst","year":"2006","unstructured":"De Genst E, et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A. 2006;103(12):4586\u201391.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1619_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0076-6879(91)04008-C","volume":"204","author":"TA Kunkel","year":"1991","unstructured":"Kunkel TA, Bebenek K, McClary J. Efficient site-directed mutagenesis using uracil-containing DNA. Methods Enzymol. 1991;204:125\u201339.","journal-title":"Methods Enzymol"},{"issue":"3","key":"1619_CR36","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/pro.4012","volume":"30","author":"S Li","year":"2021","unstructured":"Li S, et al. Revisiting the phosphotyrosine binding pocket of Fyn SH2 domain led to the identification of novel SH2 superbinders. Protein Sci. 2021;30(3):558\u201370.","journal-title":"Protein Sci"},{"key":"1619_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2003021","author":"T Kaneko","year":"2012","unstructured":"Kaneko T, et al. Superbinder SH2 domains act as antagonists of cell signaling. Sci Signal. 2012. https:\/\/doi.org\/10.1126\/scisignal.2003021.","journal-title":"Sci Signal"},{"issue":"10","key":"1619_CR38","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1021\/acscentsci.0c01056","volume":"6","author":"L Casalino","year":"2020","unstructured":"Casalino L, et al. Beyond shielding: The roles of glycans in the SARS-CoV-2 Spike protein. ACS Cent Sci. 2020;6(10):1722\u201334.","journal-title":"ACS Cent Sci"},{"issue":"1","key":"1619_CR39","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1038\/s41467-020-19204-y","volume":"11","author":"TF Custodio","year":"2020","unstructured":"Custodio TF, et al. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. Nat Commun. 2020;11(1):5588.","journal-title":"Nat Commun"},{"issue":"1","key":"1619_CR40","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1038\/s41467-021-24905-z","volume":"12","author":"T Li","year":"2021","unstructured":"Li T, et al. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection. Nat Commun. 2021;12(1):4635.","journal-title":"Nat Commun"},{"key":"1619_CR41","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.16228","volume":"5","author":"S Moutel","year":"2016","unstructured":"Moutel S, et al. NaLi-H1: a universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. Elife. 2016;5: e16228.","journal-title":"Elife"},{"key":"1619_CR42","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.34317","volume":"7","author":"I Zimmermann","year":"2018","unstructured":"Zimmermann I, et al. Synthetic single domain antibodies for the conformational trapping of membrane proteins. Elife. 2018;7: e34317.","journal-title":"Elife"},{"issue":"6566","key":"1619_CR43","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1126\/science.abh2315","volume":"374","author":"KM Hastie","year":"2021","unstructured":"Hastie KM, et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study. Science. 2021;374(6566):472\u20138.","journal-title":"Science"},{"issue":"3","key":"1619_CR44","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","volume":"28","author":"LA VanBlargan","year":"2022","unstructured":"VanBlargan LA, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022;28(3):490\u20135.","journal-title":"Nat Med"},{"issue":"22","key":"1619_CR45","first-page":"00165","volume":"S1931\u20133128","author":"X Wang","year":"2022","unstructured":"Wang X, et al. 35B5 antibody potently neutralizes SARS-CoV-2 Omicron by disrupting the N-glycan switch via a conserved spike epitope. Cell Host Microbe. 2022;S1931\u20133128(22):00165\u201372.","journal-title":"Cell Host Microbe"},{"issue":"8","key":"1619_CR46","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.cell.2022.03.009","volume":"185","author":"C Li","year":"2022","unstructured":"Li C, et al. Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell. 2022;185(8):1389\u2013401.","journal-title":"Cell"},{"issue":"6","key":"1619_CR47","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1038\/nprot.2007.151","volume":"2","author":"R Tonikian","year":"2007","unstructured":"Tonikian R, et al. Identifying specificity profiles for peptide recognition modules from phage-displayed peptide libraries. Nat Protoc. 2007;2(6):1368\u201386.","journal-title":"Nat Protoc"},{"key":"1619_CR48","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/978-1-4939-6762-9_13","volume":"1555","author":"H Huang","year":"2017","unstructured":"Huang H, et al. Creation of phosphotyrosine superbinders by directed evolution of an SH2 domain. Methods Mol Biol. 2017;1555:225\u201354.","journal-title":"Methods Mol Biol"},{"issue":"10","key":"1619_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139695","volume":"10","author":"N Zhong","year":"2015","unstructured":"Zhong N, et al. Optimizing production of antigens and fabs in the context of generating recombinant antibodies to human proteins. PLoS ONE. 2015;10(10): e0139695.","journal-title":"PLoS ONE"},{"issue":"1","key":"1619_CR50","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1080\/22221751.2020.1815589","volume":"9","author":"HL Xiong","year":"2020","unstructured":"Xiong HL, et al. Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells. Emerg Microbes Infect. 2020;9(1):2105\u201313.","journal-title":"Emerg Microbes Infect"},{"issue":"4","key":"1619_CR51","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nmeth.4193","volume":"14","author":"SQ Zheng","year":"2017","unstructured":"Zheng SQ, et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat Methods. 2017;14(4):331\u20132.","journal-title":"Nat Methods"},{"issue":"1","key":"1619_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsb.2015.11.003","volume":"193","author":"K Zhang","year":"2016","unstructured":"Zhang K. Gctf: real-time CTF determination and correction. J Struct Biol. 2016;193(1):1\u201312.","journal-title":"J Struct Biol"},{"issue":"3","key":"1619_CR53","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani A, et al. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods. 2017;14(3):290\u20136.","journal-title":"Nat Methods"},{"issue":"9","key":"1619_CR54","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/nmeth.2115","volume":"9","author":"SH Scheres","year":"2012","unstructured":"Scheres SH, Chen S. Prevention of overfitting in cryo-EM structure determination. Nat Methods. 2012;9(9):853\u20134.","journal-title":"Nat Methods"},{"issue":"1","key":"1619_CR55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nmeth.2727","volume":"11","author":"A Kucukelbir","year":"2014","unstructured":"Kucukelbir A, Sigworth FJ, Tagare HD. Quantifying the local resolution of cryo-EM density maps. Nat Methods. 2014;11(1):63\u20135.","journal-title":"Nat Methods"},{"issue":"6483","key":"1619_CR56","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp D, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260\u20133.","journal-title":"Science"},{"issue":"13","key":"1619_CR57","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen EF, et al. UCSF Chimera\u2013a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605\u201312.","journal-title":"J Comput Chem"},{"issue":"Pt 12 Pt 1","key":"1619_CR58","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60(Pt 12 Pt 1):2126\u201332.","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"Pt 2","key":"1619_CR59","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams PD, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 2):213\u201321.","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"Pt 1","key":"1619_CR60","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen VB, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 1):12\u201321.","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"1619_CR61","doi-asserted-by":"publisher","first-page":"W320","DOI":"10.1093\/nar\/gku316","volume":"42","author":"X Robert","year":"2014","unstructured":"Robert X, Gouet P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 2014;42:W320-324.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1619_CR62","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/pro.3235","volume":"27","author":"TD Goddard","year":"2018","unstructured":"Goddard TD, et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 2018;27(1):14\u201325.","journal-title":"Protein Sci"},{"issue":"1","key":"1619_CR63","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen EF, et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 2021;30(1):70\u201382.","journal-title":"Protein Sci"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01619-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-022-01619-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01619-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T19:07:21Z","timestamp":1663268841000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-022-01619-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1619"],"URL":"https:\/\/doi.org\/10.1186\/s12951-022-01619-y","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"assertion":[{"value":"28 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors agreed to publish the data in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.Z. was an intern of Noventi Biopharmaceuticals Co., Ltd. Y.Y., L.L., D.J., and H.H. are employees of Noventi Biopharmaceuticals Co., Ltd. X.Y. is an employee of Guangxi Asia United Antibody Medical Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"411"}}